Limits...
The Effects of Anti-Dementia and Nootropic Treatments on the Mortality of Patients with Dementia: A Population-Based Cohort Study in Taiwan.

Wu CY, Hu HY, Chow LH, Chou YJ, Huang N, Wang PN, Li CP - PLoS ONE (2015)

Bottom Line: Their data were compared with 12,193 age- and sex-matched non-dementia controls that were randomly selected from the same database.VaD with nootropics had a lower mortality (HR: 1.25, 95% CI: 1.15-1.37) than VaD without medication (HR: 2.46, 95% CI: 2.22-2.72).Pharmacological treatments have beneficial effects for patients with dementia in prolonging their survival.

View Article: PubMed Central - PubMed

Affiliation: Department of Dermatology, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Public Health & Department of Public Health, National Yang-Ming University, Taipei, Taiwan.

ABSTRACT

Background: Few studies have examined the contribution of treatment on the mortality of dementia based on a population-based study.

Objective: To investigate the effects of anti-dementia and nootropic treatments on the mortality of dementia using a population-based cohort study.

Methods: 12,193 incident dementia patients were found from 2000 to 2010. Their data were compared with 12,193 age- and sex-matched non-dementia controls that were randomly selected from the same database. Dementia was classified into vascular (VaD) and degenerative dementia. Mortality incidence and hazard ratios (HRs) were calculated.

Results: The median survival time was 3.39 years (95% confidence interval [CI]: 2.88-3.79) for VaD without medication, 6.62 years (95% CI: 6.24-7.21) for VaD with nootropics, 3.01 years (95% CI: 2.85-3.21) for degenerative dementia without medication, 8.11 years (95% CI: 6.30-8.55) for degenerative dementia with anti-dementia medication, 6.00 years (95% CI: 5.73-6.17) for degenerative dementia with nootropics, and 9.03 years (95% CI: 8.02-9.87) for degenerative dementia with both anti-dementia and nootropic medications. Compared to the non-dementia group, the HRs among individuals with degenerative dementia were 2.69 (95% CI: 2.55-2.83) without medication, 1.46 (95% CI: 1.39-1.54) with nootropics, 1.05 (95% CI: 0.82-1.34) with anti-dementia medication, and 0.92 (95% CI: 0.80-1.05) with both nootropic and anti-dementia medications. VaD with nootropics had a lower mortality (HR: 1.25, 95% CI: 1.15-1.37) than VaD without medication (HR: 2.46, 95% CI: 2.22-2.72).

Conclusion: Pharmacological treatments have beneficial effects for patients with dementia in prolonging their survival.

No MeSH data available.


Related in: MedlinePlus

Kaplan-Meier survival estimates.The median survival times were 9.23 years for the non-dementia group, 3.39 years for vascular dementia without medications, and 6.62 years for vascular dementia with nootropics.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4476616&req=5

pone.0130993.g003: Kaplan-Meier survival estimates.The median survival times were 9.23 years for the non-dementia group, 3.39 years for vascular dementia without medications, and 6.62 years for vascular dementia with nootropics.

Mentions: The median survival times were 3.01 years (95% CI: 2.85–3.21) for degenerative dementia without medications, 8.11 years (95% CI: 6.30–8.55) for degenerative dementia with anti-dementia medications, 6.00 years (95% CI: 5.73–6.17) for degenerative dementia with nootropics, and 9.03 years (95% CI: 8.02–9.87) for degenerative dementia with both nootropic and anti-dementia medications (Fig 2). The median survival times were 3.39 years (95% CI: 2.88–3.79) for VaD without medications, and 6.62 years (95% CI: 6.24–7.21) for VaD with nootropics (Fig 3).


The Effects of Anti-Dementia and Nootropic Treatments on the Mortality of Patients with Dementia: A Population-Based Cohort Study in Taiwan.

Wu CY, Hu HY, Chow LH, Chou YJ, Huang N, Wang PN, Li CP - PLoS ONE (2015)

Kaplan-Meier survival estimates.The median survival times were 9.23 years for the non-dementia group, 3.39 years for vascular dementia without medications, and 6.62 years for vascular dementia with nootropics.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4476616&req=5

pone.0130993.g003: Kaplan-Meier survival estimates.The median survival times were 9.23 years for the non-dementia group, 3.39 years for vascular dementia without medications, and 6.62 years for vascular dementia with nootropics.
Mentions: The median survival times were 3.01 years (95% CI: 2.85–3.21) for degenerative dementia without medications, 8.11 years (95% CI: 6.30–8.55) for degenerative dementia with anti-dementia medications, 6.00 years (95% CI: 5.73–6.17) for degenerative dementia with nootropics, and 9.03 years (95% CI: 8.02–9.87) for degenerative dementia with both nootropic and anti-dementia medications (Fig 2). The median survival times were 3.39 years (95% CI: 2.88–3.79) for VaD without medications, and 6.62 years (95% CI: 6.24–7.21) for VaD with nootropics (Fig 3).

Bottom Line: Their data were compared with 12,193 age- and sex-matched non-dementia controls that were randomly selected from the same database.VaD with nootropics had a lower mortality (HR: 1.25, 95% CI: 1.15-1.37) than VaD without medication (HR: 2.46, 95% CI: 2.22-2.72).Pharmacological treatments have beneficial effects for patients with dementia in prolonging their survival.

View Article: PubMed Central - PubMed

Affiliation: Department of Dermatology, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Public Health & Department of Public Health, National Yang-Ming University, Taipei, Taiwan.

ABSTRACT

Background: Few studies have examined the contribution of treatment on the mortality of dementia based on a population-based study.

Objective: To investigate the effects of anti-dementia and nootropic treatments on the mortality of dementia using a population-based cohort study.

Methods: 12,193 incident dementia patients were found from 2000 to 2010. Their data were compared with 12,193 age- and sex-matched non-dementia controls that were randomly selected from the same database. Dementia was classified into vascular (VaD) and degenerative dementia. Mortality incidence and hazard ratios (HRs) were calculated.

Results: The median survival time was 3.39 years (95% confidence interval [CI]: 2.88-3.79) for VaD without medication, 6.62 years (95% CI: 6.24-7.21) for VaD with nootropics, 3.01 years (95% CI: 2.85-3.21) for degenerative dementia without medication, 8.11 years (95% CI: 6.30-8.55) for degenerative dementia with anti-dementia medication, 6.00 years (95% CI: 5.73-6.17) for degenerative dementia with nootropics, and 9.03 years (95% CI: 8.02-9.87) for degenerative dementia with both anti-dementia and nootropic medications. Compared to the non-dementia group, the HRs among individuals with degenerative dementia were 2.69 (95% CI: 2.55-2.83) without medication, 1.46 (95% CI: 1.39-1.54) with nootropics, 1.05 (95% CI: 0.82-1.34) with anti-dementia medication, and 0.92 (95% CI: 0.80-1.05) with both nootropic and anti-dementia medications. VaD with nootropics had a lower mortality (HR: 1.25, 95% CI: 1.15-1.37) than VaD without medication (HR: 2.46, 95% CI: 2.22-2.72).

Conclusion: Pharmacological treatments have beneficial effects for patients with dementia in prolonging their survival.

No MeSH data available.


Related in: MedlinePlus